ISDA

Entry Detail

PDB ID:

4OTR

Keywords:

Title:

Crystal structure of BTK kinase domain complexed with 6-cyclopropyl-2-[3-[5-[[5-(4-ethylpiperazin-1-yl)-2-pyridyl]amino]-1-methyl-6-oxo-3-pyridyl]-2-(hydroxymethyl)phenyl]-8-fluoro-isoquinolin-1-one

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Spodoptera frugiperda

PDB Version:

Deposition Date:

2014-02-14

Release Date:

2014-05-14

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.95 Å

R-Value Free:

0.22

R-Value Work:

0.18

R-Value Observed:

0.18

Space Group:

P 21 21 2

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Tyrosine-protein kinase BTK
Mutations:M489A, R492A, E624A, K625A
Chain IDs:A
Chain Length:283
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:Q06187 Pfam ID:PF07714 EC:2.7.10.2

Ligand Molecules

2V3

DMS

Primary Citation

Structure-Based Drug Design of RN486, a Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis.

Lou, Y, Han, X, Kuglstatter, A, Kondru, R.K, Sweeney, Z.K, Soth, M, McIntosh, J, Litman, R, Suh, J, Kocer, B, Davis, D, Park, J, Frauchiger, S, Dewdney, N, Zecic, H, Taygerly, J.P, Sarma, K, Hong, J, Hill, R.J, Gabriel, T, Goldstein, D.M, Owens, T.D.Show

J.Med.Chem. 58 512 516 (2015)

PMID: 24712864 DOI: 10.1021/jm500305p

Abstact

Structure-based drug design was used to guide the optimization of a series of selective BTK inhibitors as potential treatments for Rheumatoid arthritis. Highlights include the introduction of a benzyl alcohol group and a fluorine substitution, each of which resulted in over 10-fold increase in activity. Concurrent optimization of drug-like properties led to compound 1 (RN486) (J. Pharmacol. Exp. Ther. 2012 , 341 , 90), which was selected for advanced preclinical characterization based on its favorable properties.

Legend

Protein

Chemical

Disease

Primary Citation of related structures